NanoViricides Inc. (NNVC)

[seeker_of_value]

Dr. Seymour gave an excellent reply to my questions. Here is his reply.

Seeker

I read everything that's posted about NNVC anywhere on the Web

I understand the concerns of most investors who are watching the stock price slowly deteriorate in spite of nothing but positive results from the Company. The real indicator is the progress of the Company over the past 6 months. When we first started the Company 6 years ago, we had a long way to go. I now see the light at the end of the tunnel...dim but getting brighter by the day!

Groundbreaking results for HIV;
Groundbreaking results for influenza;
Successful deployment of optimization program to improve previously reported FluCide efficacies;
Dengue and herpes of the eye, skin and genitals studies in the works;
Acquisition of new 18,000 foot space;
Development of specifications for a cGMP plant to be built in the new facility. (Actually, the cGMP facility will be built to our specifications offsite, then delivered and installed in the new building. The company building the plant are experts in building cGMP facilities. We have experience with this because the Level 3 Biosafety facility that we used in Vietnam was paid for by the Japanese government, built in Sweden and shipped to the site in Hanoi where it was installed by technicians from the Swedish factory);
Hiring of premier FDA consulting firm;
On-going preparation of documents for the pre-IND submission, now with the assistance of the Biologics Consulting Group;
Acquisition of enough money now in the bank to bring the first drug into the FDA;
Personal guarantees by Dr. Diwan for the acquisition of the building, construction of the plant and outfitting both with the necessary equipment;
Now pursuing an international strategy for approvals in countries other than the US;
I was personally contacted by the Health Ministers of two countries who want us to bring FluCide to their countries for testing as soon as possible (we won't even consider those offers until we have production capabilities from the cGMP plant);
Multiple offers to address both scientific and investor groups (six accepted in Sept/Oct alone);

Not bad for a Company that spends a fraction of what other biotechs do. And speaking other other biotechs, just look at the $6B market cap of VRUS that has compounds in trials for Hep C and wants to out license their HIV drug. Essentially they're looking at one disease while we have 9 indications in our pipeline (IV and IM applications for FluCide), herpes of the skin, genitals and eyes, dengue hemorrhagic fever and dengue fever, HIV and epidemic keratoconjunctivitis. I know that I'll get criticized by those who say we should focus. We are VERY focussed on getting FluCide into the FDA and as we've previously announced, we'll do our best to bring one new drug to the FDA every 6 months. It's the first one that's the tough one. After that, it should be a lot easier. Each one of these indications addresses a multi-billion dollar market.

Money is not holding us back. Everything that we're doing takes time, no matter how much money is available. Also, no one should repeat the 4 employee fiction. It just isn't true. All of that info will be available in the 10K. We are searching far and wide for qualified PhD's who don't need a lot of hand-holding to get up to speed. These people are more difficult to find than you can imagine. Credit our education system for sending too many people to Wall Street and not enough to the lab benches

There is a succession plan. My role will be to become the medical director/advisor and we'll bring in people who are experienced pharma executives to handle sales and production.

There has been a lot of talk surrounding September 30th and the pre-IND filing. As others on this Board have said, you only file when the dossier is absolutely ready. All of the data to be included in the filing comes from outside sources, something over which we have no control.

People worry about competing technologies....like the DRACO system from MIT. Read the scientific paper and then decide for yourselves whether or not they represent a challenge. They will then have to go through the same process as we will so no one can leapfrog to the front of the line. Our animal data is unassailable. Others have a long way to go to match what we've done over the past 6 years (and the 14 years prior that Dr. Diwan was working on this)!

Finally, in our favor, the trials are short for FluCide. After all, influenza is a time-limited disease from which you recover (unless you die as two of my friends and a number of my patients have already done...the latest 18 months ago from the H1N1 that was circulating in 2009. Dead in 24 hours). Initial human trials will take weeks, not months nor years

And here's a little note from the Chief Medical Officer of Sanofi with my comments following:

With healthcare costs under scrutiny, the pressure is on payers to understand the value of new products, Lehner noted. “That puts pressure on us early in development. We need new evidence in parallel with clinical trials: not just safety and efficacy, but also effectiveness.”
“Randomized trials are not going to be enough for payers in the future,” said Brian Sweet, executive director of development for AstraZeneca. “Being able to show proof that your drug is good for the healthcare cost system has never been more important than now.”

This is wonderful news for us, particularly with regard to the flu since I feel we can cut 5-6 days from the average length of hospitalization with FluCide!!! So whatever we charge, it's irrelevant because of the hospital days saved. For a sick elderly patient with the flu, I would imagine that the daily hospital costs in the ICU will exceed $5000 per day. Saving $25K while spending $2K for our drug is a no brainer (drug charges for the intravenous preparation for extremely ill patients and daily hospital costs are just estimates for the purpose of comparisons. Outpatient drug cost would be 10% of that figure {all estimates})

Hope that I have answered everyone's concerns

Sincerely,

EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics
http://www.nanoviricides.com
[e-mail]